Pfizer Inc. - Product Pipeline Review - 2015
Summary
Global Markets Directs, Pfizer Inc. - Product Pipeline Review - 2015, provides an overview of the Pfizer Inc.s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Pfizer Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA ), route of administration (RoA ) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of Pfizer Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pfizer Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Pfizer Inc.s pipeline products
Reasons to buy
- Evaluate Pfizer Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pfizer Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pfizer Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pfizer Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pfizer Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Pfizer Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table Of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Pfizer Inc. Snapshot 8
Pfizer Inc. Overview 8
Key Information 8
Key Facts 8
Pfizer Inc. - Research and Development Overview 9
Key Therapeutic Areas 9
Pfizer Inc. - Pipeline Review 21
Pipeline Products by Stage of Development 21
Pipeline Products - Monotherapy 22
Pipeline Products - Combination Treatment Modalities 23
Pipeline Products - Partnered Products 24
Pipeline Products - Out-Licensed Products 27
Pfizer Inc. - Pipeline Products Glance 31
Pfizer Inc. - Late Stage Pipeline Products 31
Pfizer Inc. - Clinical Stage Pipeline Products 36
Pfizer Inc. - Early Stage Pipeline Products 42
Pfizer Inc. - Drug Profiles 45
(oxycodone hydrochloride + naltrexone ) ER 45
(piperacillin sodium + tazobactam sodium ) 47
bazedoxifene acetate 48
crizotinib 49
tofacitinib 52
tafamidis meglumine 56
adalimumab biosimilar 58
axitinib 59
bevacizumab biosimilar 62
bococizumab 63
bosutinib 64
dacomitinib 66
diazepam 68
ertugliflozin 69
gosogliptin 70
infliximab biosimilar 71
inotuzumab ozogamicin 72
meningococcal meningitis [serotype B] vaccine 74
palbociclib 76
pregabalin 80
pregabalin CR 82
rituximab biosimilar 83
rivipansel sodium 84
sildenafil citrate 86
sunitinib malate 88
trastuzumab biosimilar 92
agatolimod sodium 93
ascrinvacumab 96
Dekavil 97
fosdagrocorat 98
glasdegib 99
MultiStem 101
PF-00489791 104
PF-00547659 105
PF-02545920 107
PF-03084014 108
PF-03715455 109
PF-04236921 110
PF-04457845 111
PF-04634817 112
PF-04937319 113
PF-04965842 115
PF-05089771 116
PF-05175157 118
PF-05212377 119
PF-06252616 120
PF-06290510 121
PF-06291874 123
PF-06372865 124
PF-06425090 125
PF-06473871 126
ponezumab 128
tanezumab 130
temsirolimus 132
ziprasidone hydrochloride 134
gedatolisib 135
PF-06463922 137
PF-06747775 139
celecoxib 140
HIV vaccine 142
KUX-1151 143
PD-0325901 + PF-05212384 144
PF-04518600 145
PF-04958242 146
PF-05082566 147
PF-05206388 148
PF-05230907 149
PF-05280602 150
PF-05402536 151
PF-06260414 152
PF-06263276 153
PF-06263507 154
PF-06273340 155
PF-06282999 156
PF-06293620 157
PF-06342674 158
PF-06409577 159
PF-06412562 160
PF-06413367 161
PF-06427878 162
PF-06444752 163
PF-06444753 164
PF-06480605 165
PF-06647020 166
PF-06647263 167
PF-06648671 168
PF-06649751 169
PF-06650808 170
PF-06650833 171
PF-06651600 172
PF-06664178 173
PF-06669571 174
PF-06678552 175
PF-06687859 176
PF-06700841 178
PF-4447943 179
Antibody to Antagonize IL-7 Receptor for Type 1 Diabetes 180
Biologics for Undisclosed Indication 181
Biologics to Target PCSK-9 for Undisclosed Indication 182
CE-355621 183
Drugs for Duchenne Muscular Dystrophy 184
GIBH-1008 185
GIBH-1010 186
GIBH-1018 187
GL-2045 188
HSD-621 189
Monoclonal Antibodies for Solid Tumor 190
NIC7-DT 191
NOX-B11 192
PF-06380101 193
PF-06447475 194
PF-2988403 195
PF-3306138 196
PF-3826719 197
PF-3845 198
PF-4942847 199
PF-4989216 200
PF-5006739 201
PNU-120596 202
Proteins to Agonize MC4R for Obesity 203
RBT-301 204
Small Molecule for Neurological Disorders 205
Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor 206
Small Molecule to Inhibit HPGDS for Asthma 207
Small Molecule to Inhibit IDO1 for Cancer 208
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections 209
Small Molecule to Inhibit TDO-2 for Cancer 210
Small Molecule to Modulate Androgen Receptor for Muscle Disorders 212
Small Molecules to Activate CFTR for Cystic Fibrosis 213
Small Molecules to Inhibit NMT for Malaria 214
Small Molecules to Inhibit PDE2 for Osteoarthritis Pain 215
Vaccine 2 for Undisclosed Indication 216
Antisense Oligonucleotide for Undisclosed Indication 217
Drug to Agonize Melanocortin Receptor 3 for Rheumatoid Arthritis and Inflammation 218
Monoclonal Antibody Conjugate for Cancer 219
Monoclonal Antibody Conjugates for Oncology 220
PF-00190434 221
PF-04445597 222
PF-2311200 223
PF-2345185 224
PF-2614170 225
PF-3604861 226
PF-3686093 227
PF-46396 228
PPD-1 229
Small Molecule to Agonize LXR for Inflammation 230
Small Molecule to Antagonize Ghrelin for Alcoholism 231
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease 232
Small Molecule to Inhibit NS5A for HCV 233
Small Molecule to Inhibit PI3K and mTOR for Cancer 234
Small Molecule to Inhibit Pin1 for Cancer 235
Small Molecule to Target AGTR1 and PPAR gamma for Hypertension and Metabolic Syndrome 236
Small Molecules for Inflammatory and Orphan Diseases 237
Small Molecules for Obesity and Diabetes 238
Small Molecules for Ulcerative Colitis and Crohn's Disease 239
Small Molecules to Agonize A1 Adenosine Receptor for Undisclosed Indication 240
Pfizer Inc. - Pipeline Analysis 241
Pfizer Inc. - Pipeline Products by Target 241
Pfizer Inc. - Pipeline Products by Route of Administration 248
Pfizer Inc. - Pipeline Products by Molecule Type 249
Pfizer Inc. - Pipeline Products by Mechanism of Action 250
Pfizer Inc. - Recent Pipeline Updates 256
Pfizer Inc. - Dormant Projects 307
Pfizer Inc. - Discontinued Pipeline Products 314
Discontinued Pipeline Product Profiles 319
Pfizer Inc. - Company Statement 342
Pfizer Inc. - Locations And Subsidiaries 347
Head Office 347
Other Locations & Subsidiaries 347
Appendix 374
Methodology 374
Coverage 374
Secondary Research 374
Primary Research 374
Expert Panel Validation 374
Contact Us 374
Disclaimer 375
List Of Tables
Pfizer Inc., Key Information 23
Pfizer Inc., Key Facts 23
Pfizer Inc. - Pipeline by Indication, 2015 25
Pfizer Inc. - Pipeline by Stage of Development, 2015 36
Pfizer Inc. - Monotherapy Products in Pipeline, 2015 37
Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2015 38
Pfizer Inc. - Partnered Products in Pipeline, 2015 39
Pfizer Inc. - Partnered Products/ Combination Treatment Modalities, 2015 40
Pfizer Inc. - Out-Licensed Products in Pipeline, 2015 42
Pfizer Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 43
Pfizer Inc. - Pre-Registration, 2015 46
Pfizer Inc. - Filing rejected/Withdrawn, 2015 47
Pfizer Inc. - Phase III, 2015 48
Pfizer Inc. - Phase II, 2015 51
Pfizer Inc. - Phase I, 2015 54
Pfizer Inc. - Preclinical, 2015 57
Pfizer Inc. - Discovery, 2015 59
Pfizer Inc. - Pipeline by Target, 2015 257
Pfizer Inc. - Pipeline by Route of Administration, 2015 263
Pfizer Inc. - Pipeline by Molecule Type, 2015 264
Pfizer Inc. - Pipeline Products by Mechanism of Action, 2015 265
Pfizer Inc. - Recent Pipeline Updates, 2015 271
Pfizer Inc. - Dormant Developmental Projects,2015 322
Pfizer Inc. - Discontinued Pipeline Products, 2015 329
Pfizer Inc., Other Locations 362
Pfizer Inc., Subsidiaries 362
List Of Figures
Pfizer Inc. - Pipeline by Top 10 Indication, 2015 25
Pfizer Inc. - Pipeline by Stage of Development, 2015 36
Pfizer Inc. - Monotherapy Products in Pipeline, 2015 37
Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2015 38
Pfizer Inc. - Partnered Products in Pipeline, 2015 39
Pfizer Inc. - Out-Licensed Products in Pipeline, 2015 42
Pfizer Inc. - Pipeline by Top 10 Target, 2015 256
Pfizer Inc. - Pipeline by Top 10 Route of Administration, 2015 263
Pfizer Inc. - Pipeline by Top 10 Molecule Type, 2015 264
Pfizer Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 265
